The Korean journal of internal medicine

The Korean Association of Internal Medicine (대한내과학회)
권호 표지
DOI QR코드

DOI QR Code

Navigating the risks of using concomitant antipeptic agents in light of osteoporotic concerns

  • Hae Won Yoo (Digestive Disease Center and Research Institute, Department of Internal Medicine, Soonchunhyang University College of Medicine) ;
  • Su Jin Hong (Digestive Disease Center and Research Institute, Department of Internal Medicine, Soonchunhyang University College of Medicine)
  • Received : 2024.02.15
  • Accepted : 2024.02.23
  • Published : 2024.03.01
Download PDF
⟨ Previous Next ⟩

Abstract

Keywords

References

  1. Shin GY, Park JM, Hong J, Cho YK, Yim HW, Choi MG. Use of proton pump inhibitors vs histamine 2 receptor antagonists for the risk of gastric cancer: population-based cohort study. Am J Gastroenterol 2021;116:1211-1219. https://doi.org/10.14309/ajg.0000000000001167
  2. Freedberg DE, Kim LS, Yang YX. The risks and benefits of long-term use of proton pump inhibitors: expert review and best practice advice from the American Gastroenterological Association. Gastroenterology 2017;152:706-715. https://doi.org/10.1053/j.gastro.2017.01.031
  3. Lo CH, Ni P, Yan Y, et al. Association of proton pump inhibitor use with all-cause and cause-specific mortality. Gastroenterology 2022;163:852-861.e2. https://doi.org/10.1053/j.gastro.2022.06.067
  4. Ghosh G, Schnoll-Sussman F, Mathews S, Katz PO. Reported proton pump inhibitor side effects: what are physician and patient perspectives and behaviour patterns? Aliment Pharmacol Ther 2020;51:121-128. https://doi.org/10.1111/apt.15522
  5. Park JH, Lee J, Yu SY, et al. Comparing proton pump inhibitors with histamin-2 receptor blockers regarding the risk of osteoporotic fractures: a nested case-control study of more than 350,000 Korean patients with GERD and peptic ulcer disease. BMC Geriatr 2020;20:407.
  6. Liu J, Li X, Fan L, Yang J, Wang J, Sun J, Wang Z. Proton pump inhibitors therapy and risk of bone diseases: an update meta-analysis. Life Sci 2019;218:213-223. https://doi.org/10.1016/j.lfs.2018.12.058
  7. Li J, Xie X, Liu W, et al. Acid-suppressive drugs and risk of fracture in children and young adults: a meta-analysis of observational studies. Front Pharmacol 2021;12:712939.
  8. Kim JM, Lin C, Stavre Z, Greenblatt MB, Shim JH. Osteoblast-osteoclast communication and bone homeostasis. Cells 2020;9:2073.
  9. Yang YX, Lewis JD, Epstein S, Metz DC. Long-term proton pump inhibitor therapy and risk of hip fracture. JAMA 2006;296:2947-2953. https://doi.org/10.1001/jama.296.24.2947
  10. Oh DJ, Nam JH, Lee HS, Moon YR, Lim YJ. The combined use of anti-peptic agents is associated with an increased risk of osteoporotic fracture: a nationwide case-control study. Korean J Intern Med 2024 Feb 7 [Epub]. DOI: 10.3904/kjim.2023.326.